These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 16102030)
1. Mechanisms of homocysteine-induced atherothrombosis. Lentz SR J Thromb Haemost; 2005 Aug; 3(8):1646-54. PubMed ID: 16102030 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Wilson KM; Lentz SR Semin Vasc Med; 2005 May; 5(2):163-71. PubMed ID: 16047268 [TBL] [Abstract][Full Text] [Related]
4. Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. Dayal S; Lentz SR Antioxid Redox Signal; 2007 Nov; 9(11):1899-909. PubMed ID: 17822370 [TBL] [Abstract][Full Text] [Related]
5. [Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease?. 1. Basic data]. Guilland JC; Favier A; Potier de Courcy G; Galan P; Hercberg S Pathol Biol (Paris); 2003 Mar; 51(2):101-10. PubMed ID: 12801808 [TBL] [Abstract][Full Text] [Related]
6. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Stühlinger MC; Tsao PS; Her JH; Kimoto M; Balint RF; Cooke JP Circulation; 2001 Nov; 104(21):2569-75. PubMed ID: 11714652 [TBL] [Abstract][Full Text] [Related]
7. Homocysteine-Induced Endothelial Dysfunction. Lai WK; Kan MY Ann Nutr Metab; 2015; 67(1):1-12. PubMed ID: 26201664 [TBL] [Abstract][Full Text] [Related]
8. Protective vascular and cardiac effects of inducible nitric oxide synthase in mice with hyperhomocysteinemia. Dayal S; Blokhin IO; Erger RA; Jensen M; Arning E; Stevens JW; Bottiglieri T; Faraci FM; Lentz SR PLoS One; 2014; 9(9):e107734. PubMed ID: 25226386 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. Weiss N Curr Drug Metab; 2005 Feb; 6(1):27-36. PubMed ID: 15720205 [TBL] [Abstract][Full Text] [Related]
10. Murine models of hyperhomocysteinemia and their vascular phenotypes. Dayal S; Lentz SR Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1596-605. PubMed ID: 18556571 [TBL] [Abstract][Full Text] [Related]
11. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Dayal S; Rodionov RN; Arning E; Bottiglieri T; Kimoto M; Murry DJ; Cooke JP; Faraci FM; Lentz SR Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H816-25. PubMed ID: 18567702 [TBL] [Abstract][Full Text] [Related]
13. Influence of hyperhomocysteinemia on the cellular redox state--impact on homocysteine-induced endothelial dysfunction. Weiss N; Heydrick SJ; Postea O; Keller C; Keaney JF; Loscalzo J Clin Chem Lab Med; 2003 Nov; 41(11):1455-61. PubMed ID: 14656025 [TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698 [TBL] [Abstract][Full Text] [Related]
15. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Austin RC; Lentz SR; Werstuck GH Cell Death Differ; 2004 Jul; 11 Suppl 1():S56-64. PubMed ID: 15243582 [TBL] [Abstract][Full Text] [Related]
16. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia. Magné J; Huneau JF; Borderie D; Mathé V; Bos C; Mariotti F Amino Acids; 2015 Sep; 47(9):1975-82. PubMed ID: 25792109 [TBL] [Abstract][Full Text] [Related]
17. Folic acid reduces adhesion molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia. Li M; Chen J; Li YS; Feng YB; Gu X; Shi CZ Int J Cardiol; 2006 Jan; 106(2):285-8. PubMed ID: 16183151 [TBL] [Abstract][Full Text] [Related]